Previous 10 | Next 10 |
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “ Making...
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “ Making...
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtrati...
2023-11-02 04:19:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Discovery Fund was down 5.4% during Q3, which was 2.0% better than the Benchmark...
2023-10-31 13:16:08 ET Repligen Corporation (RGEN) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Sondra Newman – Head of Investor Relations Tony Hunt – Chief Executive Officer Jason Garland – Chief Financia...
Repligen Corporation (NASDAQ: RGEN) is one of today's top gainers. The company's shares are currently up -4.79% on the day to $113.85. Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Euro...
2023-10-31 07:32:39 ET More on Repligen Repligen: Current Market Values Well Supported, Valuations Are Not, Reiterate Hold Repligen Corporation (RGEN) Q2 2023 Earnings Call Transcript Repligen Q3 2023 Earnings Preview Repligen beats bottom line, but misses to...
Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 million Orders strengthened with total book-to-bill ratio of 1.07 Narrows full year revenue guidance to range of $635-$645 million WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE)...
Tennant Company (TNC) is expected to report for Q3 2023 Stellantis N.V. (STLA) is expected to report for Q3 2023 Marathon Petroleum Corporation (MPC) is expected to report $7.79 for Q3 2023 Easterly Government Properties Inc. (DEA) is expected to report $0.29 for Q3 2023 Allegion ...
Repligen Corporation (RGEN) is expected to report $0.14 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC Capital Markets’ 2024 Global Hea...
Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-year Increased Filtration (non-COVID) revenue by 12% year-over-year Achieved a nine-month book-to-bill ratio of 1.03 WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Rep...